Mark W. Hahn
2018 - Dova Pharmaceuticals
In 2018, Mark W. Hahn earned a total compensation of $5.1M as Chief Financial Officer at Dova Pharmaceuticals.
Compensation breakdown
| Option Awards | $4,741,177 |
|---|---|
| Salary | $358,854 |
| Other | $7,414 |
| Total | $5,107,445 |
Hahn received $4.7M in option awards, accounting for 93% of the total pay in 2018.
Hahn also received $358.9K in salary and $7.4K in other compensation.
Rankings
In 2018, Mark W. Hahn's compensation ranked 1,953rd out of 14,244 executives tracked by ExecPay. In other words, Hahn earned more than 86.3% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 1,953 out of 14,244 | 86th |
Division Manufacturing | 705 out of 5,765 | 88th |
Major group Chemicals And Allied Products | 233 out of 2,128 | 89th |
Industry group Drugs | 185 out of 1,817 | 90th |
Industry Pharmaceutical Preparations | 143 out of 1,391 | 90th |
Source: SEC filing on March 15, 2019.
Hahn's colleagues
We found three more compensation records of executives who worked with Mark W. Hahn at Dova Pharmaceuticals in 2018.